---
title: "LLM-Driven Medical Data Startups: Sources, Constraints, and Opportunities"
date: "October 26, 2026"
geometry: margin=1in
fontsize: 11pt
---

# 1. Summary

This report looks at building an LLM-based startup around collecting and structuring data (for example, building datasets), with a focus on healthcare. It covers three things:

1. **The market.** General-purpose "AI scraping" is crowded and turning into a commodity. Startups win on a specific dataset or workflow for a specific buyer.
2. **Six well-known medical data platforms** (UWorld, AMBOSS, Figure 1, Radiopaedia, VisualDx, Sermo). None of them is a viable scraping target, for legal, licensing and privacy reasons.
3. **Viable paths.** Licensing and partnerships, products built on open data that generate their own proprietary data, and clinician-validated evaluation data for AI companies.

**Main conclusion:** every platform reviewed has a moat built on data its own product generated (user answers, searches, polls, contributed cases), not on content it scraped. A durable startup in this space should follow the same pattern.

# 2. The Market for LLM-Based Scraping

## 2.1 The generic scraping layer is crowded

Many well-funded companies already sell some version of "LLM turns web pages into structured data":

- Firecrawl, Apify, Browserbase, Exa, Diffbot, Bright Data, Kadoa

A generic "AI scraper" is a feature these companies can add, not a defensible company. The opportunity is in **owning a specific dataset or workflow that a specific buyer pays for.** Customers pay for the answer, not for the scraping.

## 2.2 What makes a data business durable

- **Recurring change.** If the underlying data changes often, the product is a subscription. Static data makes for one-off consulting work.
- **Entity resolution and validation.** LLMs have made extraction cheap. Linking, deduplicating and confidence-scoring records is the hard and defensible part.
- **Legally clean sources.** Prefer public government data, published documents, and sources used with explicit permission. Avoid scraping behind logins and anything that contains patient health information (PHI).
- **A buyer who already pays humans to do the work.** This gives a clear ROI case and fast validation.

## 2.3 Healthcare opportunities using public data

| Idea | Description | Likely buyers |
|---|---|---|
| Payer medical policy tracker | Structure insurer coverage and prior-auth policies from PDFs; detect and alert on changes | Pharma market access, revenue-cycle companies, specialty clinics, prior-auth startups |
| Provider directory accuracy | Cross-check NPPES, payer directories, practice websites and licensing boards to produce confidence-scored provider records | Payers (CMS compliance), digital health referral platforms, recruiters |
| Price transparency normalization | Normalize hospital and payer machine-readable price files for a narrow use case | Self-funded employers, contract negotiators (incumbents: Turquoise Health, Serif) |
| Clinical trial and competitive intelligence | Combine ClinicalTrials.gov, abstracts, press releases, SEC filings and FDA/EMA data by indication | Biotech business development, investors, consultancies |
| Regulatory monitoring | Summarize and route state Medicaid bulletins, pharmacy board rules and CMS transmittals | Compliance teams, providers, pharmacies |

Of these, the **payer medical policy tracker** fits best: the pain is clear, the documents are hard to parse without LLMs, change tracking makes it naturally recurring, and buyers have budget.

# 3. Review of Six Medical Data Platforms

## 3.1 Overview

| Platform | Core asset | Accessible for scraping? |
|---|---|---|
| UWorld | Board-prep question bank with answer-level performance data from millions of students | No: paywalled, copyrighted, performance data is internal |
| AMBOSS | Integrated knowledge library and question bank, plus learner and clinician search data | No: login-gated, search data is internal |
| Figure 1 | Crowdsourced clinical images with physician comments and diagnostic discussion | No: login-gated, patient image consent and privacy risk |
| Radiopaedia | Tens of thousands of curated radiology cases with annotated imaging and diagnoses | Publicly viewable but licensed CC BY-NC-SA (no commercial use); commercial licensing is available |
| VisualDx | Diagnostic image library (strong in dermatology) tagged with clinical metadata | No: paid product, licensed images |
| Sermo | Physician-only forum with case discussions and large-scale physician polling | No: restricted to verified physicians, polling data is their commercial product |

## 3.2 Platform notes

**UWorld.** The most valuable asset isn't the questions, which are copyrighted, but the performance data: which distractors mislead which learners, and how often. That data never appears publicly.

**AMBOSS.** Besides its curated content, AMBOSS has behavioral data on what clinicians and learners search for. That's a signal of real-world information needs, and it's entirely internal.

**Figure 1.** Clinical images are high-risk even when de-identified. Consent was given for use on the platform, not for redistribution or training third-party models.

**Radiopaedia.** The most "open" platform on the list, but its non-commercial license rules out direct commercial reuse. It has licensed data commercially before, so a partnership is a realistic route.

**VisualDx.** A commercial product built on licensed images and expert tagging. The tagging and clinical metadata are the value, and they're proprietary.

**Sermo.** Its physician polling and discussion data is sold to pharma and research firms. Scraping it would mean taking the company's core revenue product.

## 3.3 Risks of scraping these platforms

- **Contractual:** violating terms of service, particularly for login-gated content.
- **Copyright:** commercial use of copyrighted questions, text and images.
- **Licensing:** violating the non-commercial terms of Creative Commons content.
- **Privacy and consent:** redistributing clinical images and patient-related content outside the consent under which they were shared.
- **Business:** healthcare buyers and investors run data-provenance diligence. Data obtained improperly can block sales, fundraising and acquisition.

# 4. The Core Lesson: Product-Generated Data Moats

Each platform's defensibility comes from data its own users generate:

| Platform | Content that attracts users | Proprietary data users generate |
|---|---|---|
| UWorld | Questions and explanations | Answer-level performance |
| AMBOSS | Knowledge library | Search and query behavior |
| Figure 1 | Case feed | Contributed images and discussion |
| Radiopaedia | Case library | Contributed and curated cases |
| VisualDx | Diagnostic tools | Clinical usage and expert tagging |
| Sermo | Physician community | Polls and case discussion |

Content brings users in, and users produce data no competitor can copy. A new company should aim for the same loop and not try to copy the content.

# 5. Viable Strategic Paths

## 5.1 License or partner

Some of these platforms (for example Radiopaedia, VisualDx and Sermo) already license or sell data. A startup can add value on top through structuring, benchmarking or building AI evaluation sets, under a licensing or revenue-share agreement. The partnership itself becomes a barrier to entry.

## 5.2 Build on open data, then generate proprietary data

Start with openly licensed sources to launch a product, then capture usage data from it. Sources with friendlier licensing:

- **PubMed Central Open Access, commercial-use subset:** case reports with images.
- **MedPix (National Library of Medicine):** medical images and teaching cases.
- **ISIC Archive:** dermatology images (licenses vary per image).
- **The Cancer Imaging Archive (TCIA):** imaging collections (licenses vary per collection).
- **openFDA:** drug labels, adverse events, device data.

Check the license for each dataset, and each subset, before commercial use.

Examples: a case-based learning tool, a diagnostic reasoning trainer, or a clinical AI evaluation workbench. In each, user interactions become the proprietary dataset over time.

## 5.3 Clinician-validated evaluation data for AI companies

Model developers and health-AI startups increasingly need clinically validated benchmarks and expert-graded responses. A possible pipeline:

1. Use LLMs to draft clinical cases and questions from openly licensed literature.
2. Have paid, credentialed clinicians review, correct and grade them.
3. Sell the validated evaluation sets, or run evaluations as a service.

The moat is the expert-validation pipeline and the accumulated grading data, which parallels UWorld's performance data. This path fits an "LLM + datasets" thesis best and avoids the legal risks above.

# 6. Recommendations

1. **Don't scrape the six platforms reviewed.** The legal, licensing and privacy risks are incompatible with a fundable healthcare company.
2. **Pick one path:**
    - *Public data, recurring workflow:* payer medical policy tracker (Section 2.3).
    - *AI-era data product:* clinician-validated evaluation data (Section 5.3).
3. **Design for a product-generated data moat from day one.** Decide what proprietary data the product will accumulate through use.
4. **Validate cheaply before building:**
    - Policy tracker: structure the policies for one drug class from the top 10 payers and show the result to five market-access or revenue-cycle professionals.
    - Evaluation data: produce 50 clinician-validated cases in one specialty and pitch them to three health-AI companies.
5. **Pick a focus area early:** medical education, diagnostic imaging, or physician opinion data. Each leads to a different company, buyer and data strategy.

# 7. Open Questions

- What domain access does the team have (clinical background, academic or hospital network, existing contacts)?
- Is the goal a venture-scale company or a profitable data business?
- Which buyer is easiest to reach first: pharma, payers, providers, educators, or AI companies?
